Early disease detection: a collaborative approach

Global biopharmaceutical company UCB is investing £1 billion in research and development, including a new state-of-the-art facility, continuing the UK’s reputation as a world-leading base for global life sciences research and industry. The programme, backed by up to £79 million of government funding, will study five million healthy people in a bid to develop new diagnostic tests using artificial intelligence (AI).

This story is Premium Content and is only available to registered users. If you don't already have an account, please register with us completely free of charge.

Other news

Upcoming Events


Technological University Dublin
3-4 September 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

IBMS Biomedical Science Congress

ICC, Birmingham
22-25 September 2019

Lab Innovations

NEC, Birmingham (Hall 12)
30 & 31 October 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Jun 2019

Recent advances in cancer diagnostics

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.